search
Back to results

Vascular Function, Fish Protein Hydrolysates and Type 2 Diabetes Mellitus

Primary Purpose

Diabetes Mellitus, Type 2

Status
Completed
Phase
Not Applicable
Locations
Brazil
Study Type
Interventional
Intervention
Placebo
Fish protein hydrolysates
Sponsored by
Universidade Federal do Rio de Janeiro
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2 focused on measuring Vascular function, Type 2 diabetes mellitus, Fish protein hydrolysates

Eligibility Criteria

18 Years - 90 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Type 2 diabetes mellitus

Exclusion Criteria:

  • History of symptomatic coronary artery disease;
  • Stroke or other known atherosclerotic disease;
  • Cancer;
  • HIV positive;
  • Alcohol or drug abuse within the past 6 months previous the visit 1;
  • use any antioxidant supplementation

Sites / Locations

  • Federal University of Rio de Janeiro

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

No Intervention

Placebo Comparator

Active Comparator

Arm Label

Health control

DM Placebo

DM FHP

Arm Description

Health young subjects free of diabetes mellitus and nutritional intervention

Sucralose

Fish protein hydrolysates

Outcomes

Primary Outcome Measures

Flow-mediated dilation
macrovascular endothelial function
Near infrared spectroscopy
microvascular endothelial function
High performance liquid chromatography
serum amino acids

Secondary Outcome Measures

Full Information

First Posted
October 18, 2017
Last Updated
December 11, 2019
Sponsor
Universidade Federal do Rio de Janeiro
search

1. Study Identification

Unique Protocol Identification Number
NCT03318913
Brief Title
Vascular Function, Fish Protein Hydrolysates and Type 2 Diabetes Mellitus
Official Title
Effect of Acute Fish Protein Hydrolysates Ingestion on Vascular Function of the Type 2 Diabetes Subjects
Study Type
Interventional

2. Study Status

Record Verification Date
December 2019
Overall Recruitment Status
Completed
Study Start Date
October 23, 2017 (Actual)
Primary Completion Date
February 15, 2018 (Actual)
Study Completion Date
March 28, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Universidade Federal do Rio de Janeiro

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease of abnormal carbohydrate metabolism which is related with high morbidity and mortality rates caused by its complications. One of the major diabetes-related arterial phenotypes thought to be responsible for development of cardiovascular disease is endothelial dysfunction. Nitric oxide (NO) is a potent molecule derived of endothelium, which plays key role in control of vascular tone. In T2DM present endothelial dysfunction due to reduced NO bioavailability. Fish protein hydrolysates (FPH) have been showed to present antioxidant peptides (and high value of ACE inhibition activity. Therefore, the present study aimed to examine whether single dose of FPH ingestion would reversal macro- and microvascular endothelial dysfunction in T2DM.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
Keywords
Vascular function, Type 2 diabetes mellitus, Fish protein hydrolysates

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Masking Description
Double blind
Allocation
Randomized
Enrollment
22 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Health control
Arm Type
No Intervention
Arm Description
Health young subjects free of diabetes mellitus and nutritional intervention
Arm Title
DM Placebo
Arm Type
Placebo Comparator
Arm Description
Sucralose
Arm Title
DM FHP
Arm Type
Active Comparator
Arm Description
Fish protein hydrolysates
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
5g of the sucralose administered as white plastic capsules
Intervention Type
Other
Intervention Name(s)
Fish protein hydrolysates
Intervention Description
5g of the FPH dissolving in 100 mL of water
Primary Outcome Measure Information:
Title
Flow-mediated dilation
Description
macrovascular endothelial function
Time Frame
60 min after nutritional intervention
Title
Near infrared spectroscopy
Description
microvascular endothelial function
Time Frame
70 min after nutritional intervention
Title
High performance liquid chromatography
Description
serum amino acids
Time Frame
75 min after nutritional intervention

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Type 2 diabetes mellitus Exclusion Criteria: History of symptomatic coronary artery disease; Stroke or other known atherosclerotic disease; Cancer; HIV positive; Alcohol or drug abuse within the past 6 months previous the visit 1; use any antioxidant supplementation
Facility Information:
Facility Name
Federal University of Rio de Janeiro
City
Macaé
State/Province
Rio De Janeiro
ZIP/Postal Code
27979000
Country
Brazil

12. IPD Sharing Statement

Learn more about this trial

Vascular Function, Fish Protein Hydrolysates and Type 2 Diabetes Mellitus

We'll reach out to this number within 24 hrs